NEW YORK (360Dx) – Synergies between new draft regulatory guidance and a recently released research framework on Alzheimer's disease are expected to increase the use of biomarker diagnostics in evaluating Alzheimer's disease, experts said.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.